Background Elagolix is effective and safe for treating menorrhagia in women with uterine
fibroid. However, it is reported to be associated with hypoestrogenism that can be alleviated …

Background Uterine fibroids are one of the most common neoplasms found among women
globally, with a prevalence of approximately 11 million women in the United States alone …

Background Uterine fibroids are hormone-responsive neoplasms that are associated with
heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist …

Objective To review data of elagolix plus estradiol and norethindrone acetate as add-back
therapy for the treatment of heavy menstrual bleeding (HMB) in premenopausal women with …

Objective To investigate efficacy of elagolix plus add-back therapy (1 mg estradiol and 0.5
mg norethindrone acetate once daily) on patient-reported nonbleeding symptoms and …

Objective To evaluate the impact of elagolix, an oral gonadotropin-releasing hormone
antagonist, on the health-related quality of life (HRQL) in women with heavy menstrual …

Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …

METHODS: This double-blind, randomized, placebo-controlled, parallel group study
evaluated the efficacy and safety of 6 months of treatment in 2 cohorts, with four arms/cohort …

Objective: To assess outcomes of women with uterine fibroids (UFs) and heavy menstrual
bleeding (HMB) treated with 300 mg elagolix twice daily plus add-back therapy (E2 1 …

Objective Elagolix is an oral, non-peptide, gonadotropin-releasing hormone antagonist.
Elagolix was evaluated in premenopausal women with heavy menstrual bleeding (HMB;> …